CTLA4 and hypothyroidism: In terms of frequency, hypothyroidism is more common, affecting 15% of patients receiving ICI-combination therapy, 3% of patients receiving anti-CTLA-4, and 8% of patients receiving anti-PD-(L)1 therapy (34).